Oral Drug for Prostate Cancer Lincoln NE

But no reduced death risk in patients with localized disease, research Oral sodium clodronate improves overall survival in advanced prostate cancer patients but doesn't reduce the risk of death in those with localized disease, British researchers say. They reported on the long-term survival outcomes of more than 800 men enrolled in two trials launched in 1994. The trials examined the effects of sodium clodronate in patients with advanced (311 men) or localized prostate cancer (508 men).

Alan Richard Berg, MD
(402) 484-4900
201 South 68th Place Ste 200
Lincoln, NE
Specialties
Oncology (Cancer), Internal Medicine
Gender
Male
Education
Medical School: Univ Of Nd Sch Of Med, Grand Forks Nd 58201
Graduation Year: 1980

Data Provided by:
Bennett R Barrios
(402) 327-7300
201 S 68th Street Pl
Lincoln, NE
Specialty
Radiation Oncology

Data Provided by:
Leonard Le, MR
(402) 489-8821
120 Wedgewood Dr Ste A
Lincoln, NE
Specialties
Oncology (Cancer)
Gender
Male
Education
Graduation Year: 2007

Data Provided by:
Wallace Carroll Peterson, MD
(402) 420-7000
201 S 68th Street Pl Ste 200
Lincoln, NE
Specialties
Oncology (Cancer)
Gender
Male
Education
Medical School: Univ Of Ne Coll Of Med, Omaha Ne 68198
Graduation Year: 1982

Data Provided by:
Wallace Cary Peterson
(402) 420-7000
201 S 68th Street Pl
Lincoln, NE
Specialty
Hematology / Oncology

Data Provided by:
Phillip R Hynes
(402) 327-7300
201 South 68th Street Place
Lincoln, NE
Specialty
Radiation Oncology

Data Provided by:
Mark D Carlson
(402) 420-7000
201 S 68th Street Pl
Lincoln, NE
Specialty
Hematology / Oncology

Data Provided by:
Stacey K Knox
(402) 420-7000
201 S 68th Street Pl Ste 200
Lincoln, NE
Specialty
Hematology / Oncology

Data Provided by:
Alan R Berg
(402) 420-7000
201 S 68th Street Pl
Lincoln, NE
Specialty
Hematology / Oncology

Data Provided by:
Nathan B Green
(402) 420-7000
201 S 68th Street Pl
Lincoln, NE
Specialty
Hematology / Oncology

Data Provided by:
Data Provided by:

Oral Drug for Prostate Cancer

Provided By:

Oral sodium clodronate improves overall survival in advanced prostate cancer patients but doesn't reduce the risk of death in those with localized disease, British researchers say.

They reported on the long-term survival outcomes of more than 800 men enrolled in two trials launched in 1994. The trials examined the effects of sodium clodronate in patients with advanced (311 men) or localized prostate cancer (508 men).

The advanced prostate cancer patients who received the drug had a 23 percent lower death rate than patients who took a placebo. After five years, overall survival was 30 percent among men who took oral sodium clodronate and 21 percent among those in the placebo group. After 10 years, the survival rates were 17 percent and 9 percent, respectively, the researchers found.

However, the drug offered no improvement in overall survival to men with localized prostate cancer. After five years, overall survival was 78 percent among those who took clodronate and 80 percent among those given a placebo. After 10 years, the survival rates were 48 percent and 51 percent, respectively.

The findings are believed to be the first "to show an overall survival benefit conferred by an oral bisphosphonate when given in addition to standard hormone therapy to men with bone metastases who are starting or responding to hormone therapy," wrote Matthew Sydes, of the Medical Research Council Clinical Trials Unit, and colleagues. "However, there is no evidence that clodronate is of any benefit when given as an adjuvant to treatment in men with non-metastatic prostate cancer."

The study appears online and in the September print issue of The Lancet Oncology.

More information

The U.S. National Cancer Institute has more about prostate cancer treatment.

SOURCE: The Lancet Oncology, news release, Aug. 10, 2009

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com